Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Chooses Pfizer And Moderna For COVID-19 Boosters, But Questions Remain On Unpublished Trial Data

AstraZeneca's Vaccine Not Selected

Executive Summary

The UK’s choice of the mRNA vaccines as COVID-19 boosters is no surprise – but not releasing the key study data behind the decision is.

You may also be interested in...



Biden’s Trump Moment? COVID Booster Messaging Complicated After Top FDA Scientists Raise Doubts

As questions of political interference continue to swirl around the issue of whether additional vaccine shots will be needed, the Biden administration is facing communication challenges commonly seen with his predecessor, Donald Trump.

UK Trial Could Help Pick Best Covid Vaccine Boosters

Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.

Sofinnova Raises €472m To Build Europe’s Biggest Early-Stage Investment Fund

The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel